Lucinactant
| Clinical data | |
|---|---|
| Trade names | Surfaxin |
| ATC code | |
| Identifiers | |
| CAS Number | |
| UNII | |
Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome.[1] It is a pulmonary surfactant for infants who lack enough natural surfactant in their lungs. Whereas earlier medicines of the class, such as beractant (Survanta & Beraksurf), calfactant (Infasurf), and poractant (Curosurf), are derived from animals, lucinactant is synthetic. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012.[2]
Medical uses
Lucinactant is indicated to improve lung function and reduce duration and risk of mechanical ventilation in children. It can be used up to two years of age and is specified for children who are diagnosed with acute respiratory failure following exposure to a pathogen such as RSV or influenza, including H1N1.[3][4][5] Lucinactant is also used to treat meconium aspiration syndrome.[5][6]
Chemistry
Lucinactant contains the peptide sinapultide (KL4 acetate, KLLLLKLLLLKLLLLKLLLLK), dipalmitoylphosphatidylcholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG, as the sodium salt), and palmitic acid.
History
The scientific groundwork for lucinactant was laid in the laboratory of Charles Cochrane at The Scripps Research Institute in the 1990s.[7] The drug was then developed by Discovery Laboratories of Warrington, PA. The path through the approval process was unusually long, reflecting in part challenges in the manufacturing process that needed to be addressed before approval was granted.[8]
Legal status
Lucinactant is listed as an Orphan Drug Product by the US Food and Drug Administration for several conditions:[9][10]
- 07-30-1996 Treatment of meconium aspiration syndrome in newborn infants
- 07-17-1995 Treatment of acute respiratory distress syndrome in adults.
- 05-23-2006 Prevention of bronchopulmonary dysplasia in premature infants
- 10-21-2005 Treatment of bronchopulmonary dysplasia in premature infants.
- 10-18-1995 Treatment of respiratory distress syndrome in premature infants.
Clinical trials in Latin America were criticized for protocol based in potentially unethical principles.[11] A placebo was used and considered ethical by design since infants born in Latin America usually do not have access to life saving treatment. The intent of Discovery Labs was always to market Surfaxin in the United States, implying burdens on the Latin American children that outweighed the benefits.
References
- ^ "Surfaxin". Discovery Labs. Archived from the original on April 20, 2009.
- ^ "FDA approves Surfaxin to prevent breathing disorder in premature infants". Fda.gov. 2012-03-06. Retrieved 2012-10-20.
- ^ "POPG, a Key Component of Discovery Labs' KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach". Archived from the original on January 22, 2010.
- ^ Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, et al. (October 1999). "Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome". American Journal of Respiratory and Critical Care Medicine. 160 (4): 1188–95. doi:10.1164/ajrccm.160.4.9808118. PMID 10508806.
- ^ a b Donn SM (March 2005). "Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome". Expert Opinion on Investigational Drugs. 14 (3): 329–34. doi:10.1517/13543784.14.3.329. PMID 15833063. S2CID 6843316.
- ^ Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, et al. (June 2002). "A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome". Pediatrics. 109 (6): 1081–7. doi:10.1542/peds.109.6.1081. PMID 12042546.
- ^ "Scripps Research Discoveries Lead to Newly Approved Drug for Infant Respiratory Distress Syndrome". Scripps.edu. 2012-03-06. Retrieved 2012-10-20.
- ^ "Pharmaceutical News - Discovery Labs Turns Focus To Surfaxin Market Strategy - October 20, 2012". Pharmacy Choice. Retrieved 2012-10-20.
- ^ "List Of Orphan Products Designations And Approvals". Google2.fda.gov. Retrieved 2012-10-20.
- ^ "US FDA grants "orphan drug" status for sinapultide (Surfaxin) for chronic lung disease in premature infants". Nelm.nhs.uk. Archived from the original on 2010-04-14. Retrieved 2012-10-20.
- ^ Charatan F (March 2001). "Surfactant trial in Latin American infants criticised". BMJ. 7286. 322 (7286): 575. doi:10.1136/bmj.322.7286.620. PMC 1119782. PMID 11238147.